Shahid, M., Subhan, F., Ahmad, N., Ali, G., Akbar, S., Fawad, K. and Sewell, Robert David Edmund 2017. Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. European Journal of Pain 21 (4) , pp. 668-680. 10.1002/ejp.971 |
Preview |
PDF
- Accepted Post-Print Version
Download (1MB) | Preview |
Abstract
Background: Systemic gabapentin is a mainstay treatment for neuropathic pain though there are side effects. Localized therapy may curtail such side effects so a topical gabapentin dermal application was examined in the chronic constriction injury (CCI) model of neuropathic pain. Methods: Partial denervation CCI was achieved by rat sciatic nerve ligation. Gabapentin gel (10% w/w) was applied three-times daily on the ipsilateral or contralateral plantar surface of the hind-paw while in a concurrent systemic study, gabapentin was intraperitoneally administered daily (75 mg/kg) for 30 days. Tests for static- and dynamic- mechano-allodynia (paw withdrawal threshold [PWT] to von-Frey filament application and latency [PWL] to light brushing), coldallodynia (paw withdrawal duration [PWD] to acetone), heat- (PWL and PWD) and mechanohyperalgesia (PWD to pin-prick) were utilized to assess pain while effects on locomotion (open field) and motor balance (rotarod and footprint-analysis) were measured on days 5-30 postsurgery. Results: Topical application of gabapentin gel ipsilaterally but not contralaterally alleviated CCI-induced static- (days 10-30) and dynamic-allodynia (days 15-30), suppressed cold-allodynia (days 10-30), heat- (days 15-30) and mechano-hyperalgesia (days 5-30) indicating a local action. Systemic gabapentin exhibited similar pain profiles but was associated with motor impairment. The gabapentin gel formulation afforded desirable neuropathic pain alleviating effects devoid of unwanted systemic side-effects. Conclusions: These outcomes disclose an expedient pharmacological validation of the effectiveness of topical gabapentin gel against an extensive range of nociceptive stimulus modalities utilizing the CCI-induced neuropathic pain model. They also advocate further clinical studies on topical gabapentin with regard to certain neuropathic pain syndromes.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy |
Subjects: | R Medicine > RS Pharmacy and materia medica |
Uncontrolled Keywords: | Gabapentin gel; neuropathic pain; allodynia and hyperalgesia; localized therapy, no motor impairment |
Publisher: | Wiley |
ISSN: | 1090-3801 |
Date of First Compliant Deposit: | 22 February 2017 |
Date of Acceptance: | 21 September 2016 |
Last Modified: | 07 Nov 2023 04:06 |
URI: | https://orca.cardiff.ac.uk/id/eprint/98465 |
Citation Data
Cited 33 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |